*To the Editor:* The emergency conditions imposed by the coronavirus disease 2019 (COVID-19)[@bib1] pandemic have forced drug regulatory agencies, from the Food and Drug Administration to the European Medicines Agency, to allow the use of drugs that are not tested and approved for this precise condition. Severe cutaneous adverse drug reactions[@bib2] are rare, ranging from 5 cases per million of acute generalized exanthematous pustulosis and drug reaction with eosinophilia systemic symptoms to 1 case per million of toxic epidermal necrolysis. However, hundreds of lives could be affected if millions of patients are exposed. The cutaneous adverse drug reactions rate may increase as a consequence of the virus and drug interactions, as already occurs with Epstein-Barr virus, cytomegalovirus, human herpesvirus 6, and HIV. Thus, reporting cases is of paramount importance to allow pharmacovigilance agencies to estimate the effective incidence. [Table I](#tbl1){ref-type="table"} shows drugs empirically used to treat COVID-19 and several possible skin reaction patterns for rapid consultation by clinicians.Table IList of main drug categories and selected active principles currently used or under evaluation for COVID-19 management, with possible related cutaneous adverse reactions from the literatureDrugsCutaneous adverse reactionsSuggested references, by first authorAntipyretics (acetaminophen; cautious use of other nonsteroidal anti-inflammatory drugs is usually recommended)PruritusRashUrticaria angioedemaSJSTENDelayed hypersensitivity reactionLee SY, et al. *Allergy Asthma Immunol Res*. 2019;11(2):212-221.Watanabe H, et al. *J Dermatol.* 2016; 43(3):321-324.Halevi A, et al. *Ann Pharmacother.* 2000;34(1):32-34.Ibáñez, M.D, et al. *Allergy*. 1996;51:121-123.Hydroxychloroquine/chloroquinePruritusUrticariaAlopeciaHair bleachingMucocutaneous hyperpigmentationPhotosensitive eruptionSweet syndromePsoriasis flareExfoliative dermatitisErythrodermaAGEPGPFESJSTENDRESSSharma AN, et al. *J Am Acad Dermatol.* 2020;S0190-9622(20)30564-8.Bodard Q, et al. *Rev Med Interne.* 2020;41:289-292.Liccioli G, et al. *Pharmacology.* 2019;104(1-2):57-59.Schwartz RA, et al. *Dermatol Ther.* 2020;33(3):e13380.Pai SB, et al. *Indian J Pharmacol.* 2017; 49(1):132-134.Murphy M, et al. *Clin Exp Dermatol.* 2001;26(5):457-458.Lopinavir/ritonavir or darunavir/ritonavirPruritusMaculopapular rashUrticaria angioedemaSeborrheic dermatitisAlopeciaScleroderma-like lesionsLichenoid drug eruptionLipodystrophyNail, oral, or skin hyperpigmentationParonychiaAGEPErythema multiformeSJSVasculitisTENDRESSGhosn J, et al. *Clin Infect Dis.* 2005;41(9):1360-1361.Calista D. *Eur J Dermatol.* 2005;15(2):97-98.Manfredi R, et al. *AIDS.* 2006;20(18):2399-2400.Cvetkovic RS, et al. *Drugs*. 2003;63 (8):769-802.Ortiz R, et al. *AIDS.* 2008;22(12):1389-1397.Pistone G, et al. *Case Rep Dermatol.* 2014;6(2):145-149.Introcaso CE, et al. *J Am Acad Dermatol.* 2010;63(4):549-561.Sharma A, et al. *Indian J Dermatol Venereol Leprol.* 2008;74(3):234-237.TocilizumabRashPruritusUrticarial eruptionSkin infectionsUlcerPsoriasiform dermatitisAnaphylaxisHypersensitivity reactionKoryürek ÖM, et al. *Cutan Ocul Toxicol.* 2016;35(2):145-152.Bannwarth B, et al. *Expert Opin Drug Saf*. 2011;10(1):123-131.Matsushima Y, et al. *Case Rep Dermatol.* 2019;11(3):317-321.RemdesevirRashesGrein J, et al. *N Engl J Med.* 2020;382(24):2327-2336.Baricitinib tocilizumabUrticaria angioedemaRashPalmoplantar pustulosisHerpes simplex/zosterPsoriasiform dermatitisMelanomaNonmelanoma skin cancersPraveen D, et al. *Int J Antimicrob Agents*. 2020;4:105967.Koumaki D, et al. *Eur J Case Rep Intern Med.* 2019;7(1):001383.Matsushima Y, et al. *Case Rep Dermatol.* 2019;11(3):317-321.Antibiotic (azithromycin or other targeted drugs for secondary infections)PruritusMaculopapular exanthemUrticaria angioedemaAnaphylaxisFixed drug eruptionAGEPVasculitisSJS-TENDRESSShaeer MK, et al. *Pharmacy.* 2019;7(3):135Balakirski G, et al. *Cutan Ocul Toxicol.* 2017;36(4):307-316.Sriratanaviriyakul N, et al. *J Med Case Rep.* 2014;8:332.Khaldi N, et al. *J Clin Pharmacol.* 2005;12(3):e264-e268.Williams DA. *Mil Med.* 2000; 165(8):636-637.Antifungals (allylamine, imidazoles, or others for opportunistic infections)PruritusMaculopapular exanthemUrticaria angioedemaAGEPSJSExfoliative dermatitisSubacute LECastellsague J, et al. *BMC Dermatol.* 2002;2:14.Chaudhary RG, et al. *Indian Dermatol Online J.* 2019;10(2):125-130.Beltraminelli HS, et al. *Br J Dermatol.* 2005;152(4):780-783.Systemic corticosteroid (mainly dexamethasone)Atrophy, skin fragilityPurpuraRed stretchmarksHypertrichosisAcneiform eruptionSystemic hypersensitivityLiu D, et al. *Allerg Allergy Asthma Clin Immunol.* 2013;9(1):30.Kannan S, et al. *Indian J Pharmacol.* 2015;47(6):696-698.Watts TJ, et al. *Contact Dermatitis.* 2019;81(5):384-386.Barbaud A, et al. *Curr Pharm Des.* 2016;22(45):6825-6831.Heparin (low weight molecular)Maculopapular, exanthemaUrticarial type I reactionDelayed type hypersensitivityAGEPSkin necrosis type III Arthus reactionPhan C, et al. *Ann Dermatol Venereol.* 2014;141(1):23-29.Klos K, et al. *Contact Dermatitis*. 2011;64(1):61-62.Komeicki P et al. *J Am Acad Dermatol.* 2007;57(4):718-721.Wütschert R, et al. *Drug Saf.* 1999;20(6):25-30.IvermectinEdema of face and extremitiesPapular rashBullous skin lesionsTENBurham GM. *Trans R Soc Trop Med Hyg.* 1993;87:313-317.Seegobin K, et al. *Am J Emerg Med.* 2018;36(5):887-889.Interferons (α; β)Hair lossInduce, reveal, or worsen some dermatoses (atopic dermatitis, psoriasis, sarcoidosis, lichen)Sarcoidosis, lupusPolymorphic erythemaVasculitisLichenoid drug eruptionDescamps V. *Presse Med.* 2005;34(21):1668-1672.Li C, et al. *J Int Med Res.* 2019;47(7):3453-3457.Verma P, et al. *J Chemother.* 2017;29(6):380-382.Bush AE, et al. *J Drugs Dermatol.* 2017;16(7):714-716.Lorcy S, et al. *Ann Dermatol.* 2016;143(5):336-346.IVIgUrticariaMaculopapular exanthemAnaphylaxisAlopeciaErythema multiformeLichenoid dermatitisEczematous eruptionsPompholyxPurpuraVasculitisBerk-Krauss J, et al. *Int J Womens Dermatol.* 2018;4(3):170-173.Gerstenblith MR, et al. *J Am Acad Dermatol.* 2012;66(2):312-316.Cohen Aubart F, et al. *Eur J Intern Med.* 2009;20(1):70-73.Vecchietti G, et al. *Arch Dermatol.* 2006;142(2):213-217.[^1][^2]

A typical example of a wide spectrum of cutaneous adverse drug reactions associated with a drug used to treat COVID-19 is hydroxychloroquine, which is associated with acute generalized exanthematous pustulosis, drug reaction with eosinophilia systemic symptoms, and lethal toxic epidermal necrolysis.[@bib3] Antibiotics, as well as antiretrovirals, are associated with a high risk of drug eruptions,[@bib2] whereas other experimental drugs, such as remdesivir, are poorly characterized in the literature, with unknown frequencies and risk factors for cutaneous adverse drug reactions. Tocilizumab is a potential inhibitor of multiple cytochrome enzymes, including CYp450, and increased levels of concomitant drugs or unstable metabolites may lead to skin toxicity, as well as delayed hypersensitivity reactions. Intravenous immunoglobulins are associated with cutaneous adverse events in up to 6% of patients. A recent Italian study on skin manifestations associated with COVID-19 revealed that approximately 40% of eruptions are potentially drug related.[@bib4]

Another challenge is cutaneous adverse drug reaction management in the COVID-19 course, owing to the risk of additional adverse effects, mainly caused by drug interactions. Symptomatic treatment with antihistamines, such as mizolastine and ebastine, can prolong the QT interval and worsen the potential effects of hydroxychloroquine or azithromycin, triggering severe cardiac arrhythmia.[@bib1] Cetirizine might be a safer drug in cases of itching maculopapular and urticaria angioedema reactions. Systemic corticosteroids are controversial for severe cutaneous adverse drug reactions, with case-control analysis[@bib5] suggesting prolonged disease duration or progression, which are the same concerns that are currently emerging with COVID-19.[@bib1]

The effects of the COVID-19 pandemic are without precedent, and the exponential rate of lethal disease has entailed the use of empirical drug protocols, often borrowed from those used for other diseases, in the wait for a vaccine. Occurrence of severe cutaneous adverse drug reactions is predictable, and dire consequences can be avoided if the medical community is aware of the problem. Dermatologists\' expertise might be an added value to promptly recognize different cutaneous reaction patterns, support patient assessment, and provide adequate management.
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[^1]: Expected incidence of the events might range from common (1/100 and \<1/10 exposed persons) for pruritus, urticaria, and maculopapular exanthem to rare (1/10,000 and \<1/1000) for the majority of other reactions and to very rare for severe drug reactions (5/1 million for AGEP, SJS, and DRESS and 1/1 million for TEN).

[^2]: *AGEP*, Acute generalized exanthematous pustulosis; *DRESS*, drug reaction with eosinophilia and systemic symptoms syndrome; *GPEF*, generalized pustular figurate erythema; *IVIg*, intravenous immunoglobulins; *SJS*, Stevens-Johnson syndrome; *TEN*, toxic epidermal necrolysis.
